Lilly
Research Interests
Volunteers
Carrer With Us
 

Neuroscience



  1. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Cui YM, Teng CH, Pan AX, Yuen E, Yeo KP, Zhou Y, Zhao X, Long AJ, Bangs ME, Wise SD. Br J Clin Pharmacol. 2007 Oct;64(4):445-9. Epub 2007 Jul 4.

  2. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction. Yeo KP, Lowe SL, Lim MT, Voelker JR, Burkey JL, Wise SD. Br J Clin Pharmacol. 2006 Feb;61(2):200-10

  3. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI. Lowe SL, Yeo KP, Teng L, Soon DK, Pan A, Wise SD, Peck RW. Psychoneuroendocrinology. 2006 May;31(4):473-84. Epub 2005 Dec 27.

  4. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. Kelly RP, Yeo KP, Teng CH, Smith BP, Lowe S, Soon D, Read HA, Wise SD. J Clin Pharmacol. 2005 Jul;45(7):851-5.

  5. Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. Hua TC, Pan A, Chan C, Poo YK, Skinner MH, Knadler MP, Gonzales CR, Wise SD. Br J Clin Pharmacol. 2004 May;57(5):652-6.

  6. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Sathirakul K, Chan C, Teng L, Bergstrom RF, Yeo KP, Wise SD. Br J Clin Pharmacol. 2003 Aug;56(2):184-7.

  7. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD. Clin Pharmacol Ther. 2003 Mar;73(3):170-7.

  8. Haemodynamic Effects of Atomoxetine are less pronounced than Methylephenidate, and not Additive in Combination. American College of Clinical Pharmacology (ACCP), Virginia, September 2001

  9. Haemodynamic Effects of IV Salbutamol and Oral Atomoxetine, Alone and in Combination. American College of Clinical Pharmacology (ACCP), Virginia, September 2001